Luis F Schachner, Christopher Mullen, Wilson Phung, Joshua D Hinkle, Michelle Irwin Beardsley, Tracy Bentley, Peter Day, Christina Tsai, Siddharth Sukumaran, Tomasz Baginski, Danielle DiCara, Nicholas J Agard, Matthieu Masureel, Joshua Gober, Adel M ElSohly, Rafael Melani, John E P Syka, Romain Huguet, Michael T Marty, Wendy Sandoval
The heterogeneity inherent in today's biotherapeutics, especially as a result of heavy glycosylation, can affect a molecule's safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to analyze intact glycoproteins or other heterogeneous biotherapeutics. Here, we present an approach to the molecular assessment of biotherapeutics that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact heterogeneous and/or glycosylated proteins by mass spectrometry...
April 16, 2024: Nature Communications